If You Invested in Bowen Acquisition Corp (BOWN)
See the BOWN overviewWhat $1,000 or $10,000 in BOWN Was Worth at Its Last Close
Real historical value by amount invested and how long before the last close| If you invested | 1 year before | 5 years before | 10 years before | Since Aug 17, 2023 |
|---|---|---|---|---|
| $1,000 | $865 -14% | — | — | $908 -9% |
| $10,000 | $8,645 -14% | — | — | $9,081 -9% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2025-07-15. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for BOWN$1,000 Investment Over Time
BOWN vs S&P 500Year-by-Year Returns
BOWN annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2023Aug 17 to Dec 29 | $10.12 | $10.32 | +2.0% | +2.0% |
| 2024 | $10.32 | $10.92 | +5.8% | +7.9% |
| 2025Dec 31, 2024 to Jul 15 | $10.92 | $9.19 | -15.8% | -9.2% |
About Bowen Acquisition Corp
Financial Services · NASDAQ
Bowen Acquisition Corp (NASDAQ: BOWN) is a special purpose acquisition company (SPAC) and blank check company in the financial services sector. According to its public disclosures, Bowen Acquisition Corp was formed as a Cayman Islands exempt company with the stated business purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
The company’s efforts to identify a prospective target business are not limited to a particular industry or geographic region. However, Bowen Acquisition Corp has stated that it intends to focus its search on businesses throughout Asia. This focus is reflected in its proposed business combination with Shenzhen Qianzhi BioTechnology Co. Ltd., a health and wellness focused biotech company based in Shenzhen, China, engaged in development, manufacturing and sales of ozonated, plant-based products for antibacterial, skincare, gynecological, and andrological applications, as well as ozonated disinfectant products.
Bowen Acquisition Corp’s securities have been listed on the Nasdaq Global Market. Its ordinary shares trade under the symbol BOWN, and its rights, each entitling the holder to receive one-tenth of one ordinary share upon completion of an initial business combination (subject to adjustment), trade under the symbol BOWNR. The company initially offered units under the symbol BOWNU, with each unit consisting of one ordinary share and one right. Proceeds from its initial public offering and related private placements were placed in a trust account, consistent with the structure typically used by blank check companies.
As a SPAC, Bowen Acquisition Corp does not have an operating business of its own. Instead, its value proposition to shareholders is tied to its ability to identify, negotiate, and complete a business combination with a target company. Public filings and press releases indicate that Bowen Acquisition Corp has been working to consummate its previously announced business combination with Shenzhen Qianzhi BioTechnology Co. Ltd. and its parent entity, Qianzhi Group Holding (Cayman) Limited, under an agreement and plan of merger.
Under the merger agreement, a wholly owned subsidiary of Bowen Acquisition Corp, Bowen Merger Sub, is expected to merge with and into Qianzhi Group Holding (Cayman) Limited, with Qianzhi Group Holding surviving as a wholly owned subsidiary of Bowen Acquisition Corp. In connection with the merger, shareholders of Qianzhi Group Holding are expected to receive ordinary shares of Bowen Acquisition Corp, with the potential for additional earnout shares upon achievement of specified targets, as described in the merger agreement summary.
Bowen Acquisition Corp’s corporate governance and shareholder approvals are documented in its SEC filings. For example, an extraordinary general meeting of shareholders approved amendments to the company’s amended and restated memorandum and articles of association to extend the date by which the company must consummate a business combination by up to three one-month increments, from December 14, 2025 to as late as June 14, 2026, unless a business combination closes earlier or an earlier date is set by the board of directors.
The company has also disclosed challenges related to its Nasdaq listing. Nasdaq staff determined that Bowen Acquisition Corp was not in compliance with several Nasdaq Global Market listing rules, including requirements related to minimum market value of listed securities, minimum publicly held shares, market value of publicly held shares, and minimum total shareholders. Nasdaq issued a delisting determination letter and halted trading in the company’s securities. A Nasdaq Hearings Panel granted the company a conditional extension to remain listed, contingent on completing its business combination by a specified deadline. When that deadline was not met, the panel determined to delist the securities at the open of trading on November 3, 2025, subject to further review procedures.
Bowen Acquisition Corp has appealed Nasdaq’s determinations through the processes available under Nasdaq Listing Rules, including a request for review by the Nasdaq Listing and Hearing Review Council. The company has indicated in its public communications that there can be no assurance that its requests for continued listing or stays of suspension will be granted, or that it will be able to regain or maintain compliance with Nasdaq listing criteria.
In addition to listing-related matters, Bowen Acquisition Corp has filed notifications of late filing (Form 12b-25) with respect to certain periodic reports, such as a Quarterly Report on Form 10-Q. In these filings, the company has stated that it requires additional time to compile and process the information necessary to complete its quarterly report, citing the absence of full-time accounting and administrative staff and its ongoing efforts to consummate its initial business combination.
Bowen Acquisition Corp’s structure, disclosures, and public communications are characteristic of a SPAC in the process of pursuing a business combination, managing regulatory deadlines, and addressing stock exchange listing requirements. Investors and observers typically review its SEC filings, including Forms 8-K, 10-Q, and related proxy and registration statements, for details on its proposed merger, extensions of its business combination deadline, trust account arrangements, and any changes to its capital structure or listing status.
Business model and purpose
Business purpose: Bowen Acquisition Corp’s stated purpose is to complete a business combination with one or more businesses or entities through a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar transaction.
Target focus: While not limited to a specific sector or geography, the company has indicated that it intends to focus on businesses throughout Asia. Its announced merger agreement with Shenzhen Qianzhi BioTechnology Co. Ltd. reflects this regional focus.
SPAC structure: As a blank check company, Bowen Acquisition Corp raised capital through an initial public offering of units, with proceeds placed in a trust account. Investors in the SPAC typically receive rights that may convert into fractional shares upon completion of a qualifying business combination, as described in the company’s offering documents and subsequent press releases.
Regulatory and listing context
Bowen Acquisition Corp is subject to the reporting requirements of the Securities Exchange Act of 1934 and files periodic and current reports with the U.S. Securities and Exchange Commission (SEC). Its SEC filings provide details on its corporate governance, shareholder meetings, extensions of its business combination deadline, and its efforts to complete the proposed transaction with Shenzhen Qianzhi BioTechnology Co. Ltd.
The company has disclosed interactions with Nasdaq regarding compliance with continued listing standards, including market value and shareholder count requirements, and has described the outcomes of hearings and panel decisions related to potential delisting. These disclosures are relevant for understanding the trading status and potential risks associated with the BOWN and BOWNR securities.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Bowen Acquisition Corp investment returns
How much was $1,000 invested in Bowen Acquisition Corp worth at its last close?
If you invested $1,000 in Bowen Acquisition Corp (BOWN) 1 year before its last close, on 2024-07-15, your investment was worth $865 on 2025-07-15, a -13.5% price return without dividends, growing at a compounded rate of -13.6% per year (CAGR).
Has Bowen Acquisition Corp outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare BOWN performance over available time periods.
What is Bowen Acquisition Corp's average annual return?
The compound annual growth rate (CAGR) of BOWN’s share price over the 1 year to Jul 15, 2025 is -13.6%, without dividends. Individual years vary a great deal, and BOWN’s best recent full year was 2024 (+5.8%) while the worst was 2024 (+5.8%).
For informational and educational purposes only, not investment advice.